Weight management: Evidence-Based Supplement Guide

Weight is the fourth most common reason people in Avelor hold a supplement: 16 of 72 people with a saved stack. It is also the area where the ground has shifted fastest, because the medicines now work. **The GLP-1 and dual-agonist medicines produce weight loss of a size supplements have never approached.** Randomised trials have reported this for semaglutide (PMID 33667417, 33755728) and for tirzepatide (PMID 35658024). This guide does not treat supplements as an alternative to that, because the evidence does not support treating them as one. **The important finding for anyone taking one of those medicines is what comes off alongside the fat.** Multiple analyses report that a substantial share of the weight lost is **lean mass** (PMID 38937282, 39996356, 41068996), and a 2026 comparison examined lean-mass change with incretin therapy against lifestyle intervention (PMID 41877354). That is the single most useful thing in this guide, and it is the thing least often said on a supplement label. **What has evidence for protecting lean mass is not a supplement in isolation.** It is adequate protein and resistance training during the weight-loss period (PMID 28166780, 28514618, 35191588), and there is evidence that an energy deficit itself blunts resistance-training gains (PMID 34623696). Reviews of strategies for minimising muscle loss on incretin medicines reach compatible conclusions (PMID 39295512, 42419343). **Micronutrient intake matters more when you are eating much less**, and a 2026 review examined micronutrient and nutritional deficiencies associated with GLP-1 medicines (PMID 41549912).

1. **If you are on a GLP-1 medicine, the lean-mass question belongs with your prescriber**, not with a supplement decision (PMID 38937282). 2. **Protein adequacy and resistance training are the evidenced protective pair** during weight loss (PMID 28166780, 28514618). 3. **Eating much less makes micronutrient intake harder**, which is worth raising at a review (PMID 41549912). 4. **Tell whoever prescribes your medicines** what you take, especially given slowed gastric emptying.

The semaglutide trials ran **68 weeks** (PMID 33667417) and the tirzepatide trial **72 weeks** (PMID 35658024). The lean-mass findings are measured across those same periods. Resistance-training trials in dieting adults commonly run **several months** (PMID 28514618). Nothing here has a short-term endpoint.

- **Berberine's evidence is modest and the reviews disagree on size.** Systematic reviews and meta-analyses report effects on obesity indices (PMID 32690176, 41310257, 39042390), and they do not support treating it as comparable to a prescribed medicine. - **"Lean mass" is not the same as "muscle function".** Some analyses measure composition and some measure strength, and a change in one does not establish a change in the other (PMID 41068996). - **The protein and resistance-training evidence is mostly in people losing weight by diet**, not specifically in people on incretin medicines. The incretin-specific reviews are newer and smaller (PMID 39295512). - **No dose appears in this guide.** Dosing is a clinical decision and is held for clinician review. - **This guide has not been reviewed by a clinician.** `reviewStatus` above says so.

- **GLP-1 medicines slow how fast the stomach empties**, which can change how quickly anything else you swallow is absorbed, including other medicines. Raise timing with **the prescriber who manages your medicines**. - **Rapid weight loss with much lower food intake is where deficiencies appear.** Persistent tiredness, unsteadiness or changes in vision while eating very little should go to **a doctor promptly** rather than being treated with a supplement. - **Do not stop a prescribed weight medicine on the strength of anything here.** That is a conversation with **the prescribing clinician**. - **Berberine is not a substitute for a prescribed medicine** and should be raised with **whoever manages your diabetes or blood sugar** if you take one, because both act on blood glucose.

| Entity ID | Name | | --- | --- | | `avelor:sup:protein` | Protein (whey or plant) | | `avelor:sup:whey-protein` | Whey Protein | | `avelor:sup:creatine` | Creatine | | `avelor:sup:berberine` | Berberine | | `avelor:sup:psyllium-husk` | Psyllium husk | | `avelor:sup:multivitamin` | Multivitamin | | `avelor:sup:electrolytes` | Electrolytes | **Named and not linkable.** The GLP-1 and dual-agonist **medicines** are not supplement entities and are not linked here; they belong to the medication registry. That is correct, and it means this guide cannot be interaction-checked against the thing most of its readers are actually taking. **Resolving is not the same as being checkable.** The interaction catalogue keys on a collapsed name string rather than an entity id. Of the seven entities above, five carry a catalogue key and two do not: `psyllium-husk` and `multivitamin` display as recognised ingredients and are checked against nothing.

| PMID | Title | | --- | --- | | 33667417 | "Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial" | | 33755728 | "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial" | | 35658024 | "Tirzepatide Once Weekly for the Treatment of Obesity" | | 38937282 | "Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies" | | 39996356 | "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight" | | 41068996 | "Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study" | | 41877354 | "Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials" | | 28166780 | "Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: a randomized controlled trial" | | 28514618 | "Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults" | | 35191588 | "Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: A systematic review and meta-analysis" | | 34623696 | "Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression" | | 39295512 | "Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity" | | 42419343 | "Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement" | | 41549912 | "Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review" | | 32690176 | "The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials" | | 41310257 | "The effect of berberine on obesity indices: a systematic review and meta-analysis" | | 39042390 | "Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial" | *The only dose figure anywhere in this guide sits inside the title of PMID 33667417, which is named "Semaglutide 2.4 mg once a week in adults with overweight or obesity". It is the paper's own title, not guidance, and it is reproduced rather than edited: rewriting a cited title to satisfy a house rule would falsify the citation.*